Cargando…
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping
MET exon 14 skipping alterations (METex14) comprise a diverse set of actionable oncogene drivers in non–small-cell lung cancer (NSCLC). Recent studies have established the efficacy of tyrosine kinase inhibitors for this patient population. The landscape of co-occurring genetic alterations in METex14...
Autores principales: | Le, Xiuning, Hong, Lingzhi, Hensel, Chuck, Chen, Rongrong, Kemp, Haley, Coleman, Niamh, Ciunci, Christine A., Liu, Stephen V., Negrao, Marcelo V., Yen, Jennifer, Xia, Xuefeng, Scheuenpflug, Juergen, Stroh, Christopher, Juraeva, Dilafruz, Tsao, Anne, Hong, David, Raymond, Victoria, Paik, Paul, Zhang, Jianjun, Heymach, John V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694524/ https://www.ncbi.nlm.nih.gov/pubmed/34957368 http://dx.doi.org/10.1200/PO.21.00135 |
Ejemplares similares
-
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
por: Hong, Lingzhi, et al.
Publicado: (2021) -
Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012) -
ExonSkipDB: functional annotation of exon skipping event in human
por: Kim, Pora, et al.
Publicado: (2020) -
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022) -
Natural Exon Skipping Sets the Stage for Exon Skipping as Therapy for Dystrophic Epidermolysis Bullosa
por: Bremer, Jeroen, et al.
Publicado: (2019)